Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.51 |
| ▸ | TK2 | O00142 | 9/20 | 0.42 |
| ▸ | TK1 | P04183 | 2/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7068149 | 1.00 | TYMP (0.51) | TYMPTK2TK1HSP90AA1 | |
| SCHEMBL6515778 | 0.94 | TYMP (0.48) | TYMPTK2TK1 | |
| SCHEMBL17090761 | 0.93 | TYMP (0.51) | TYMPTK2TK1 | |
| SCHEMBL31723482 | 0.93 | TYMP (0.51) | TYMPTK2TK1 | |
| SCHEMBL5502782 | 0.93 | TYMP (0.51) | TYMPTK2TK1 | |
| SCHEMBL5888977 | 0.93 | TYMP (0.51) | TYMPTK2TK1 | |
| SCHEMBL315534 | 0.93 | TYMP (0.51) | TYMPTK2TK1 | |
| SCHEMBL22984025 | 0.91 | TYMP (0.54) | TYMPTK2TK1 | |
| SCHEMBL7702801 | 0.91 | TYMP (0.54) | TYMPTK2TK1 | |
| SCHEMBL7702799 | 0.91 | TYMP (0.54) | TYMPTK2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6593466-B1 | Monomer of given formula; modified to increase binding affinity to target DNA or RNA and resist nuclease degradation; useful as therapeutics or diagnostics; gene expression inhibition | ISIS PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| US-20030092046-A1 | Guanidinium functionalized oligomers and methods | MANOHARAN MUTHIAH (US) | 2003-05-15 | — | — | US | disclosed |
| US-6534639-B1 | Useful for diagnostic, therapeutic and investigative purposes; guanidine group gives enhanced DNA-RNA hybrid binding affinity and/or increased nuclease resistance | ISIS PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
| EP-1206574-A4 | GUANIDINIUM FUNCTIONALIZED OLIGOMERS AND METHODS | ISIS PHARMACEUTICALS INC (US) | 2002-10-16 | — | — | EP | disclosed |
| EP-1206574-A2 | GUANIDINIUM FUNCTIONALIZED OLIGOMERS AND METHODS | ISIS PHARMACEUTICALS, INC. (US) | 2002-05-22 | — | — | EP | disclosed |
| WO-2001002423-A9 | 2'-GUANIDINYL-SUBSTITUTED OLIGONUCLEOTIDES AND GENE EXPRESSION MODULATION THEREWITH | ISIS PHARMACEUTICALS INC (US) | 2002-05-02 | — | — | WO | disclosed |
| WO-2001002423-A2 | 2'-GUANIDINYL-SUBSTITUTED OLIGONUCLEOTIDES AND GENE EXPRESSION MODULATION THEREWITH | ISIS PHARMACEUTICALS, INC. (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092046-A1 | Guanidinium functionalized oligomers and methods | RNMT, RNGTT, ADAR | TYMP 571/4885TK2 428/4885TK1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.